toxemia of pregnancy

WordNet

1. the state of being pregnant; the period from conception to birth when a woman carries a developing fetus in her uterus (同)gestation, maternity
2. blood poisoning caused by bacterial toxic substances in the blood (同)toxaemia

PrepTutorEJDIC

1. 《所有・所属》…『の』,…のものである,…に属する・《材料・要素》…『でできた』,から成る・《部分》…『の』[『中の』] ・《数量・単位・種類を表す名詞に付いて》…の・《原因・動機》…『で』,のために(because of) ・《主格関係》…『の』,による,によって・《目的格関係》…『を』,の・《同格関係》…『という』・《関係・関連》…『についての』[『の』],の点で・《抽象名詞などと共に》…の[性質をもつ] ・《『It is』+『形』+『of』+『名』+『to』 doの形で,ofの後の名詞を意味上の主語として》・《分離》…『から』・《起原・出所》…『から』[『の』](out of) ・《『名』+『of』+『a』(『an』)+『名』の形で》…のような・《『名』+『of』+『mine』(『yours, his』など独立所有格)の形で》…の…・《時》(1)《副詞句を作って》…に《形容詞句を作って》…の・《時刻》《米》…前(to,《米》before)
2. 〈U〉〈C〉妊娠の状態(期間) / 〈U〉《文》含蓄
3. OLD French古[代]フランス語

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/01/30 23:52:12」(JST)

wiki en

[Wiki en表示]

Pre-eclampsia
Classification and external resources
Micrograph showing hypertrophic decidual vasculopathy, a histomorphologic finding seen in gestational hypertension - a component of pre-eclampsia. H&E stain.
ICD-10	O11, O14
ICD-9	642.4-642.7
DiseasesDB	10494
MedlinePlus	000898
eMedicine	med/1905 ped/1885
MeSH	D011225

Pre-eclampsia or preeclampsia is a medical condition characterized by high blood pressure and significant amounts of protein in the urine of a pregnant woman. If left untreated, it can develop into eclampsia, the life-threatening occurrence of seizures during pregnancy.

There are many different causes for the condition. It appears likely that there are substances from the placenta that can cause endothelial dysfunction in the maternal blood vessels of susceptible women. While blood pressure elevation is the most visible sign of the disease, it involves generalised damage to the maternal endothelium, kidneys, and liver, with the release of vasoconstrictive factors being a consequence of the original damage.

An outdated medical term for pre-eclampsia is toxemia of pregnancy, since it was thought that the condition was caused by toxins.

Pre-eclampsia may develop at any time after 20 weeks of gestation. Pre-eclampsia before 32 weeks is considered early onset, and is associated with increased morbidity. Its progress differs among patients; most cases are diagnosed before labor typically would begin. Pre-eclampsia may also occur up to six weeks after delivery. Apart from Caesarean section and induction of labor (and therefore delivery of the placenta), there is no known cure. It is the most common of the dangerous pregnancy complications; it may affect both the mother and fetus.

Causes

The pre-eclampsia syndrome is thought in many cases to be caused by a shallowly implanted placenta which becomes hypoxic, leading to an immune reaction characterized by secretion of upregulated inflammatory mediators from the placenta, and acting on the vascular endothelium. The shallow implantation is thought to stem from the maternal immune system's response to the placenta and refers to evidence suggesting a lack of established immunological tolerance in pregnancy. This results in an immune response against paternal antigens from the fetus and its placenta. In some cases of pre-eclampsia it is thought that the mother lacks the receptors for the proteins the placenta is using to downregulate the maternal immune system's response to it. This view is also consistent with evidence showing many miscarriages to be an immunological disorder where the mother's immune system "unleashes a destructive attack on the tissues of the developing child".

In many cases of the pre-eclampsia syndrome, however, the maternal response to the placenta appears to have allowed for normal implantation. It is possible that women with higher baseline levels of inflammation stemming from underlying conditions such as chronic hypertension or autoimmune disease may have less tolerance for the inflammatory burden of pregnancy.

If severe, pre-eclampsia progresses to fulminant pre-eclampsia, with headaches, visual disturbances, and epigastric pain, and further to the HELLP syndrome and eclampsia. HELLP syndrome itself is considered subtype of preeclampsia. Placental abruption is associated with hypertensive pregnancies. These are life-threatening conditions for both the developing baby and the mother.

Many theories have attempted to explain why pre-eclampsia arises, and have linked the syndrome to the presence of the following:

• endothelial cell injury
• immune rejection of the placenta
• compromised placental perfusion
• altered vascular reactivity
• imbalance between prostacyclin and thromboxane
• decreased glomerular filtration rate with retention of salt and water
• decreased intravascular volume
• increased central nervous system irritability
• disseminated intravascular coagulation
• uterine muscle stretch (ischemia)
• dietary factors, including vitamin deficiency
• Hughes syndrome
• genetic factors - There is an association between pre-eclampsia and certain variants of the genes coding for angiotensin-converting enzyme, CTLA-4, thrombin, factor V, lipoprotein lipase and plasminogen activator inhibitor-1. These genetic risk factors are generally shared with those of cardiovascular diseases in general.
• air pollution
• obesity
• Thyroid dysfunction: Subclinical hypothyroidism in early pregnancy, compared with normal thyroid function, has been estimated to increase the risk of pre-eclampsia with an odds ratio of 1.7.

The current understanding of the syndrome is as a two-stage process, with a highly variable first stage which predisposes the placenta to hypoxia, followed by the release of soluble factors which result in many of the other events in pathogenesis.

Risk factors

Known risk factors for preeclampsia include:

• Nulliparity
• Diabetes mellitus
• Renal disease
• Chronic hypertension
• Prior history of preeclampsia
• Extreme age (>35 or <15)
• Obesity
• Antiphospholipid antibody syndrome
• Multiple gestation

Pathogenesis

Although much research into the cause and mechanism of pre-eclampsia has taken place, its exact pathogenesis remains uncertain. Some studies support notions of inadequate blood supply to the placenta making it release particular hormones or chemical agents that, in mothers predisposed to the condition, leads to damage of the endothelium (lining of blood vessels), alterations in metabolism, inflammation, and other possible reactions.

Abnormalities in the maternal immune system and insufficiency of gestational immune tolerance seem to play major roles in pre-eclampsia. One of the main differences found in pre-eclampsia is a shift toward Th₁ responses and the production of IFN-γ. The origin of IFN-γ is not clearly identified and could be the natural killer cells of the uterus, the placental dendritic cells modulating responses of T helper cells, alterations in synthesis of or response to regulatory molecules, or changes in the function of regulatory T cells in pregnancy. Aberrant immune responses promoting pre-eclampsia may also be due to an altered fetal allorecognition or to inflammatory triggers. It has been documented that fetal cells such as fetal erythroblasts as well as cell-free fetal DNA are increased in the maternal circulation in women who develop pre-eclampsia. These findings have given rise to the hypothesis that pre-eclampsia is a disease process by which a placental lesion such as hypoxia allows increased fetal material into maternal circulation that leads to an immune response and endothelial damage ultimately resulting in pre-eclampsia and eclampsia.

Some studies suggest that hypoxia resulting from inadequate perfusion upregulates sFlt-1, a VEGF and PlGF antagonist, leading to a damaged maternal endothelium and restriction of placental growth. In addition, endoglin, a TGF-beta antagonist, is elevated in pregnant women who develop pre-eclampsia. Soluble endoglin is likely upregulated by the placenta in response to an upregulation of cell-surface endoglin produced by the maternal immune system, although there is also the potential that sEng is produced by the maternal endothelium. Levels of both sFlt-1 and sEng increase as severity of disease increases, with levels of sEng surpassing levels of sFlt-1 in HELLP syndrome cases. Recent data indicate that Gadd45a stress signaling regulates elevated sFlt-1 expression in pre-eclampsia. Another VEGF antagonist implicated in pathogenesis of preeclampsia is soluble fms-like tyrosine kinase-1.

Both sFlt-1 and sEng are upregulated in all pregnant women to some extent, supporting the idea that hypertensive disease in pregnancy is a normal pregnancy adaptation gone awry. As natural killer cells are intimately involved in placentation and as placentation involves a degree of maternal immune tolerance for a foreign placenta which requires maternal resources for its support, it is not surprising that the maternal immune system might respond more negatively to the arrival of some placentae under certain circumstances, such as a placenta which is more invasive than normal. Initial maternal rejection of the placental cytotrophoblasts may be the cause of the inadequately remodeled spiral arteries in those cases of pre-eclampsia associated with shallow implantation, leading to downstream hypoxia and the appearance of maternal symptoms in response to upregulated sFlt-1 and sEng.

One hypothesis for vulnerability to preeclampsia is the maternal-fetal conflict between the maternal organism and fetus. After the first trimester trophoblasts enter the spiral arteries of the mother to alter the spiral arteries and thereby gain more access to maternal nutrients. However, occasionally there is impaired trophoblast invasion that results in inadequate alterations to the uterine spiral arteries. It is hypothesized that the developing embryo releases biochemical signals that result in the woman developing hypertension and preeclampsia so that the fetus can benefit from a greater amount of maternal circulation of nutrients due to increased blood flow to the impaired placenta. This results in a conflict between the maternal organism’s Darwinian fitness and survival and the developing fetus because the fetus is invested in only its survival and fitness while the mother is invested in this pregnancy and subsequent potential pregnancies.

Another evolutionary hypothesis for vulnerability to preeclampsia is the idea of ensuring pair-bonding between the mother and father and paternal investment in the fetus. Researchers posit the idea that preeclampsia serves as an adaptation for the mother to terminate investment in a fetus that might have an unavailable paternal donor, as determined by repeated semen exposure of the paternal donor to the mother. Various studies have shown that women who frequently had exposure to partners’ semen before conception had a reduced risk of preeclampsia. Also, subsequent pregnancies by the same paternal donor had a reduced risk of preeclampsia while subsequent pregnancies by a different paternal donor had a higher risk of developing preeclampsia.

Diagnosis

Criteria

Pre-eclampsia is well diagnosed when a pregnant woman develops both:

• blood pressure >140 systolic and/or >90 diastolic (two separate readings taken at least six hours apart)
• 0.3 grams or more of protein in a 24-hour urine sample (proteinuria).

A rise in baseline blood pressure (BP) of 30 mmHg systolic or 15 mmHg diastolic, while not meeting the absolute criteria of 140/90, is still considered important to note, but is not considered diagnostic.

"Severe pre-eclampsia" involves a BP over 160/110, proteinuria more than 1 g / 24 h and signs of end organ damage (CNS) dysfunction with symptoms like headache; pulmonary edema; renal dysfunction with oliguria or creatinine over 1.5 mg/dL; hepatocellular injury with ALT more than two-fold upper normal limit; hematologic dysfunction with platelet count less than 100,000/μL or DIC; placental dysfunction with IUGR or oligohydramnios etc.)

Other symptoms

Swelling or edema (especially in the hands and face) was originally considered an important sign for a diagnosis of pre-eclampsia, but in current medical practice only hypertension and proteinuria are necessary for a diagnosis. Pitting edema (unusual swelling, particularly of the hands, feet, or face, notable by leaving an indentation when pressed on) can be significant, and should be reported to a health care provider.

Although eclampsia is potentially fatal (2% of cases), pre-eclampsia is often asymptomatic, and so its detection depends on signs or investigations. Nonetheless, one symptom is crucially important because it is often misinterpreted: epigastric pain may be confused with heartburn, a common problem of pregnancy. In general, none of the signs of pre-eclampsia are specific, and even convulsions in pregnancy are more likely to have causes other than eclampsia in modern practice. Diagnosis, therefore, depends on finding a coincidence of several pre-eclamptic features, the final proof being their regression after delivery.

Some women develop high blood pressure without proteinuria (protein in urine), which is called pregnancy-induced hypertension (PIH) or gestational hypertension. Both pre-eclampsia and PIH are regarded as very serious conditions and require careful monitoring of mother and baby.

Emerging predictive tests

Emerging tests aimed at predicting or at least quantifying the risk of pre-eclampsia include the following blood tests taken by venipuncture on the mother:

• Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFLT-1) levels in late first or second trimester appear to predict early-onset pre-eclampsia with a high sensitivity and specificity.
• Vascular endothelial growth factor (VEGF) family proteins do not have sufficient statistical power to accurately predict late-onset pre-eclampsia, but may be useful in detection of early-onset pre-eclampsia.
• Placental protein 13 (PP13) levels that are low in the first trimester of pregnancy confer a higher risk of developing pre-eclampsia later in pregnancy.

In November 2011, a new test was announced that involves checking patients' urine for specific cells called podocytes. Out of the 300 women tested, all the women who went on to have pre-eclampsia were found to have podocytes in their urine, whilst none of the women who had a normal pregnancy, or who suffered from pregnancy-induced hypertension, tested positive for podocytes.

Differential diagnosis

Pre-eclampsia can mimic and be confused with many other diseases, including chronic hypertension, chronic renal disease, primary seizure disorders, gallbladder and pancreatic disease, immune or thrombotic thrombocytopenic purpura, antiphospholipid syndrome and hemolytic-uremic syndrome. It must always be considered a possibility in any pregnant woman beyond 20 weeks of gestation. It is particularly difficult to diagnose when preexisting disease such as hypertension is present. Women with acute fatty liver of pregnancy may also present with elevated blood pressure and protein in the urine, but differs by the extent of liver damage.

Prevention

Thrombophilias may be weakly linked to pre-eclampsia. There are no high quality studies to suggest that blood thinners will prevent pre-eclampsia in thrombophilic women.

Smoking cessation

In low-risk pregnancies the association between cigarette smoking and a reduced risk of pre-eclampsia has been consistent and reproducible across epidemiologic studies. High-risk pregnancies (those with pregestational diabetes, chronic hypertension, history of pre-eclampsia in a previous pregnancy, or multifetal gestation) showed no significant protective effect. The reason for this discrepancy is not definitively known; research supports speculation that the underlying pathology increases the risk of pre-eclampsia to such a degree that any measurable reduction of risk due to smoking is swamped. A study into the effects of smoking on the incidence of pre-eclampsia in African-American women found a significantly lower incidence of pre-eclampsia with higher measured levels of nicotine. When adjusted for age, parity, and medical comorbidities the association was still observable, but no longer significant. Medical authorities and anti-smoking advocates discourage smoking in general during pregnancy.

Diet

Protein or calorie supplementation have no effect on pre-eclampsia rates, and dietary protein restriction does not appear to increase pre-eclampsia rates. Supplementation with antioxidants such as vitamin C and E have no effect. There is no evidence that changing salt intake has an effect.

Calcium supplementation in women with low-calcium diets found no change in pre-eclampsia rates but did find a decrease in the rate of severe preeclamptic complications. Low selenium status is associated with higher incidence of pre-eclampsia.

Aspirin

Low dose aspirin has moderate benefits when used for the prevention of pre-eclampsia. Start of supplementation at or before 16th week of pregnancy resulted in a substantial reduction of preterm pre-eclampsia without any effect on term pre-eclampsia.

Exercise

There is insufficient evidence to recommend either exercise or bedrest as preventative measures of pre-eclampsia.

Treatment

The only known definitive treatment for eclampsia or advancing pre-eclampsia is delivery, either by labor induction or Caesarean section of both fetus and placenta. However, post-partum pre-eclampsia may occur up to six weeks following delivery even if symptoms were not present during the pregnancy. Post-partum pre-eclampsia is dangerous to the health of the mother since she may ignore or dismiss symptoms as simple post-delivery headaches and edema. Hypertension can sometimes be controlled with anti-hypertensive medication, but any effect this might have on the progress of the underlying disease is unknown.

Blood pressure medication

Antihypertensives reduce maternal and fetal mortality among pregnancy patients with hypertension as compared to placebo according to a randomized controlled trial. Overall, after three weeks of treatment, mean arterial pressure was lower in the isradipine group, but when compared with the placebo group, the difference in mean arterial pressure did not have statistical significance. After treatment with isradipine, those patients with no proteinuria experienced a decrease of between 8.5 and 11.3 mmHg, whereas those with proteinuria experienced about only 1 mmHg difference in systolic blood pressure. Those treated with placebo in both groups did not experience much change in systolic blood pressure, regardless of proteinuria being present or not. Therefore, the authors concluded proteinuric patients may respond differently from nonproteinuric patients to this treatment, where the nonproteinuric patients responded the most to treatment with isradipine.

Labetolol, Hydralazine and Nifedipine are often the antihypertensives of choice for eclampsia or pre-eclampsia, especially Labetolol as it has little placental transfer. ACE inhibitors and angiotensin receptor blockers are contraindicated as they affect fetal development.

The target blood pressure has been proposed to be 140-160 mmHg systolic and 90-105 mmHg diastolic, although some sources recommend lower values.

Magnesium sulfate

In some cases, women with pre-eclampsia or eclampsia can be stabilized temporarily with magnesium sulfate intravenously to forestall seizures while steroid injections are administered to promote fetal lung maturation. Magnesium sulfate acts by interacting with NMDA receptors. Magnesium sulfate as a possible treatment was considered at least as far back as 1955, but only in recent years did its use in the UK replace the use of diazepam or phenytoin. Evidence for the use of magnesium sulfate came from the international MAGPIE study. When induced delivery needs to take place before 37 weeks gestation, it is accepted that there are additional risks to the baby from premature birth that will require additional monitoring and care.

Epidemiology

Pre-eclampsia affects approximately 6-8% of all pregnancies worldwide, with onset of symptoms in the late second or third trimester, most commonly after the 32nd week. Some women will experience pre-eclampsia as early as 20 weeks, though this is rare. It is much more common in women who are pregnant for the first time, and its frequency drops significantly in second pregnancies. While change of paternity in a subsequent pregnancy is now thought to lower risk except in those with a family history of hypertensive pregnancy, since increasing maternal age raises risk, it has been difficult to evaluate how significant paternity change actually is and studies are providing conflicting data on this point.

Pre-eclampsia is also more common in women who have preexisting hypertension,diabetes, autoimmune diseases such as lupus, various inherited thrombophilias such as Factor V Leiden, renal disease, women with a family history of pre-eclampsia, obese women, and women with a multiple gestation (twins or multiple birth). The single most significant risk for developing pre-eclampsia is having had pre-eclampsia in a previous pregnancy.^{[citation needed]}

Pre-eclampsia may also occur in the immediate post-partum period. This is referred to as "postpartum pre-eclampsia". The most dangerous time for the mother is the 24–48 hours postpartum and careful attention should be paid to pre-eclampsia signs and symptoms.

Eclampsia can occur after the onset of pre-eclampsia. Eclampsia, which is a more serious condition, complicates 1 in 2000 maternities in the United Kingdom and carries a maternal mortality of 1.8 percent. The HELLP syndrome is more common, probably about 1 in 500 maternities, but may be as dangerous as eclampsia itself. These two major maternal crises can present unheralded by prodromal signs of pre-eclampsia.

Complications

Cerebral autoregulation is disturbed in preeclampsia leading to increased risk of stroke. Cerebral hemorrhage is a lesion that can kill with pre-eclampsia or eclampsia. In that cerebral hemorrhage is a known complication of severe hypertension in other contexts, it must be assumed that this is a major predisposing factor in this situation, although this has not been proven. Adult respiratory distress syndrome appears to have become more common, it is not known whether this is a consequence of modern methods of respiratory support rather than of the disease itself.

Uric acid levels may help to predict maternal complications among patients with pre-eclampsia according to a systematic review and decision analysis. In this study, the sensitivity was 68% and specificity was 68%. In this study which assumed a prevalence of maternal complications was 5%, the positive predictive value of 6.2% and negative predictive value of 98.6% (click here to adjust these results for patients at higher or lower risk of maternal complications). In their clinical decision analysis, they presumed initially a distress ratio of 10 (defined as being the expected distress of severe complications valued as 10 times worse than the expected distress of a caesarean section), and under these assumptions, they concluded that there would be the least expected distress from using serum uric acid for clinical decision making. The writers of this study acknowledged that there were significant limitations to their review due to heterogeneity of the individual studies they examined with regards to several variables.

In very rare cases, temporary vision loss can occur due to partial or complete cortical blindness by petechial hemorrhages and focal vasogenic edema in the occipital cortex.

Women with preeclampsia are at higher risk of cardiovascular and renal disorders later in life.

Research

Many studies have also suggested the importance of a woman's immunological tolerance to her baby's father, whose genes are present in the young fetus and its placenta and which may pose a challenge to her immune system. As the theory is further investigated, researchers are increasingly studying the importance of a woman's continued exposure to her partner's semen as early as several years before conception. One study published in the American Journal of Obstetrics and Gynecology involved several hundreds of women and found that "women with a short period of cohabitation (less than 4 months) who used barrier methods for contraception had a substantially elevated risk for the development of pre-eclampsia compared with women with more than 12 months of cohabitation before conception". However, the results from a study conducted in 2004 show that the theory is still not conclusive. In that study, the researchers found that after adjustment and stratification, the effect of barrier contraceptive use on the development of pre-eclampsia had disappeared, with both arms having identical rates of pre-eclampsia. Although the study has since been criticized for its subjective adjustment of data, it remains important because it demonstrates that there is still some contention over the degree to which failure of tolerance induction can be attributed to prior exposure to the partner's sperm.

Continued exposure to a partner's semen has a strong protective effect against pre-eclampsia, largely due to the absorption of several immune modulating factors present in seminal fluid.

Long periods of sexual cohabitation with the same partner fathering a woman's child significantly decreased her chances of suffering pre-eclampsia. As one early study described, "although pre-eclampsia is a disease of first pregnancies, the protective effect of multiparity is lost with change of partner". The study also concluded that although women with changing partners are strongly advised to use condoms to prevent sexually transmitted diseases, "a certain period of sperm exposure within a stable relation, when pregnancy is aimed for, is associated with protection against pre-eclampsia".

Several other studies have since investigated the strongly decreased incidence of pre-eclampsia in women who had received blood transfusions from their partner, those with long, preceding histories of sex without barrier contraceptives, and in women who had been regularly performing oral sex, with one study concluding "induction of allogeneic tolerance to the paternal human leukocyte antigen (HLA) molecules of the fetus may be crucial. Data collected strongly suggest that exposure, and especially oral exposure to soluble HLA from semen can lead to transplantation tolerance."

According to the theory, the fetus and placenta both contain "foreign" proteins from paternal genes, but regular, preceding and coincident exposure to the father's semen may promote immune acceptance and subsequent implantation, a process which is significantly supported by as many as 93 currently identified immune regulating factors in seminal fluid.

Having already noted the importance of a woman's immunological tolerance to her baby's paternal genes, several Dutch reproductive biologists decided to take their research a step further. Consistent with the fact that human immune systems tolerate things better when they enter the body via the mouth, the Dutch researchers conducted a series of studies that confirmed a surprisingly strong correlation between a diminished incidence of pre-eclampsia and a woman's practice of oral sex, and noted that the protective effects were strongest if she swallowed her partner's semen. The researchers concluded that while any exposure to a partner's semen during sexual activity appears to decrease a woman's chances for the various immunological disorders that can occur during pregnancy, immunological tolerance could be most quickly established through oral introduction and gastrointestinal absorption of semen. Recognizing that some of the studies potentially included the presence of confounding factors, such as the possibility that women who regularly perform oral sex and swallow semen also engage in more frequent intercourse, the researchers also noted that, either way, "the data still overwhelmingly supports the main theory" behind all their studies—that repeated exposure to semen establishes the maternal immunological tolerance necessary for a safe and successful pregnancy.

A team from the University of Adelaide has also investigated to see if men who have fathered pregnancies which have ended in miscarriage or pre-eclampsia had low seminal levels of critical immune modulating factors such as TGF-Beta. The team has found that certain men, dubbed "dangerous males", are several times more likely to father pregnancies that would end in either pre-eclampsia or miscarriage. Among other things, most of the "dangerous males" seemed to lack sufficient levels of the seminal immune factors necessary to induce immunological tolerance in their partners.

As the theory of immune intolerance as a cause of pre-eclampsia has become accepted, women who with repeated pre-eclampsia, miscarriages, or In Vitro Fertilization failures could potentially be administered key immune factors such as TGF-beta along with the father's foreign proteins, possibly either orally, as a sublingual spray, or as a vaginal gel to be applied onto the vaginal wall before intercourse.

References

External links

• MedlinePlus entry on high blood pressure in pregnancy
• Mayo Clinic fact sheet on pre-eclampsia
• "Preeclampsia Research at the NICHD". NICHD : US Department of Health and Human Services & National Institutes of Health. 

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

• 1. 子癇前症：臨床的特徴および診断 preeclampsia clinical features and diagnosis
• 2. 子癇前症：管理および予後 preeclampsia management and prognosis
• 3. 妊婦および出産後女性における高血圧のマネージメント management of hypertension in pregnant and postpartum women
• 4. 妊娠高血圧 gestational hypertension
• 5. 重度の子癇前症の待機的マネージメント expectant management of severe preeclampsia

English Journal

• Maternal characteristics and mid-pregnancy serum biomarkers as risk factors for subtypes of preterm birth.

• Jelliffe-Pawlowski LL1,2, Baer RJ1, Blumenfeld YJ3, Ryckman KK4, O'Brodovich HM5, Gould JB5,6, Druzin ML3, El-Sayed YY2, Lyell DJ3, Stevenson DK5, Shaw GM5, Currier RJ1.
• BJOG : an international journal of obstetrics and gynaecology.BJOG.2015 Oct;122(11):1484-93. doi: 10.1111/1471-0528.13495. Epub 2015 Jun 26.
• OBJECTIVE: To examine the relationship between maternal characteristics, serum biomarkers and preterm birth (PTB) by spontaneous and medically indicated subtypes.DESIGN: Population-based cohort.SETTING: California, United States of America.POPULATION: From a total population of 1 004 039 live sing
• PMID 26111589

• Previous miscarriage and the subsequent risk of preterm birth in Scotland, 1980-2008: a historical cohort study.

• Oliver-Williams C1, Fleming M2, Wood AM1, Smith G3.
• BJOG : an international journal of obstetrics and gynaecology.BJOG.2015 Oct;122(11):1525-34. doi: 10.1111/1471-0528.13276. Epub 2015 Jan 28.
• OBJECTIVE: To determine whether the relationship between previous miscarriage and risk of preterm birth changed over the period 1980-2008, and to determine whether the pattern varied according to the cause of the preterm birth.DESIGN: Linked birth databases.SETTING: All Scottish NHS hospitals.POPULA
• PMID 25626593

• Supplementation of vitamin D in pregnancy and its correlation with feto-maternal outcome.

• Sablok A1, Batra A1, Thariani K1, Batra A1, Bharti R1, Aggarwal AR2, Kabi BC3, Chellani H4.
• Clinical endocrinology.Clin Endocrinol (Oxf).2015 Oct;83(4):536-41. doi: 10.1111/cen.12751. Epub 2015 Mar 9.
• CONTEXT: Vitamin D deficiency is widely prevalent throughout the world. Pregnant women, neonates and infants form most vulnerable groups for vitamin D deficiency.OBJECTIVE: (1) To find prevalence of vitamin D deficiency in pregnant women. (2) To evaluate the effect of supplementation with cholecalci
• PMID 25683660

Japanese Journal

• 妊娠高血圧症候群と妊娠中毒症の疫学的相違 (特集 今,改めて妊娠高血圧症候群を考える)

• 片山 富博
• 産婦人科治療 102(5), 805-808, 2011-05
• NAID 40018836390

Related Links

• toxemia of pregnancy - definition of toxemia of pregnancy by ...

toxemia of pregnancy n. See preeclampsia. toxemia of pregnancy. See preeclampsia. pregnancy-induced hypertension A term that encompasses isolated (nonproteinuric) hypertension (HTN)—pre-eclampsia—or proteinuric HTN ...

• toxemia of pregnancyの意味 - 英和辞書 - 英語辞書 - goo辞書

toxemia of pregnancyとは。意味や和訳。《病》妊娠中毒症. - goo英和辞書は14万項目以上を収録し、発音、音声、慣用句、例文が分かる英和辞書です。 toxemia of pregnancyの意味 - 英和辞書 - 英語辞書 - goo辞書 |

Related Pictures

---

★リンクテーブル★

リンク元	「高尿酸血症」「pre-eclampsia」「妊娠腎」
関連記事	「toxemia」

「高尿酸血症」

　　[★]

英

hyperuricemia

同

尿酸過剰血症

関

尿酸 uric acid、血清尿酸、痛風

概念

• 尿酸の血漿中溶解度を考慮し、男女を問わず血清尿酸値7.0mg/dlを超える状態(医学事典)

病因

• 産生過剰

• 原発性

• ホスホリボシルピロリン酸 PRPPの増加
• ヒポキサンチングアニンホスホリボシルトランスフェラーゼ HGPRTの増加

• 続発性

• von Gierke病
• 多血症、慢性骨髄性白血病　←　乳酸過多による尿酸クリアランスの低下？？？、核酸分解産物の増加

• 排泄低下

• 続発性：利尿薬(サイアザイド系利尿薬、ループ利尿薬(フロセミド))

HIM.2445

• 尿酸過剰産生
• 尿酸排泄低下

• 原発性特発性
• 腎不全
• 多嚢胞性腎疾患
• 尿崩症
• 高血圧
• アシドーシス

• 乳酸アシドーシス
• 糖尿病アシドーシス

• 飢餓によるケトーシス
• ベリリウム症
• サルコイドーシス
• 鉛中毒
• 副甲状腺機能亢進症
• 甲状腺機能低下症
• toxemia of pregnancy
• バーター症候群
• ダウン症候群
• 薬物摂取(サリチル酸、利尿薬、アルコール(see HIM.2446)、レボドパ、エタンブトール、ピラジナミド、ニコチン酸、シクロスポリン)
• 高インスリン血症：高インスリン血症は腎臓での尿酸とナトリウムの排泄を減少させる(HIM.2447)

ガイドライン

• 高尿酸血症・痛風ガイドラインダイジェスト版

http://www.tukaku.jp/tufu-GL2.pdf

治療

治療開始基準

• 痛風関節炎なし

• 腫瘍崩壊症候群の予防
• 無症候性持続性高尿酸血症(9mg/dl)　←　これをトリガーにして治療するのは、ないわー、と言われている。

• 痛風関節炎あり

• 痛風結節
• 発作頻度(2回/年以上)
• CKDステージ2以上
• 尿酸結石

生活食事療法

回避すべき食習慣

• 肉(レバー、ホルモン、砂肝など)、魚類(エビ、カツオなど)、菓子パンの過剰摂取
• ビール、紹興酒など酒類： (禁酒週に２回。1日ビール500ml以下、日本酒1合以下、ウイスキー60ml以下
• 果糖/ジュースの採りすぎ
• カロリーの過剰摂取

尿酸を下げる食事

• 乳製品(スキムミルク、低脂肪ヨーグルト)
• コーヒー、ビタミンC

参考

• 1.

http://www.nmt.ne.jp/~nagioo/gout.htm

「pre-eclampsia」

　　[★]

子癇前症、妊娠中毒症

関

preeclampsia、toxemia of pregnancy

「妊娠腎」

　　[★]

英

toxemia of pregnancy

関

妊娠中毒症

「toxemia」

　　[★]

• 毒素血症、毒血症